https://doi.org/10.1016/j.annonc.2022.02.004
M
Marc Thill
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
520
Papers
5.5K
Citations
33
h-index
118
i10-index
Marc Thill is an academic researcher from University Medical Center Freiburg. The author has contributed to research in topics: Breast Cancer Treatment Studies & Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research. The author has an h-index of 33, co-authored 442 publications.
ORCID: 0000-0002-8800-8044Papers by this author
worksPathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
2022 · Annals of Oncology · 369 citations
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
2024 · New England Journal of Medicine · 168 citations
https://doi.org/10.1056/nejmoa2412063
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
2017 · European Journal of Cancer · 46 citations
https://doi.org/10.1016/j.ejca.2017.05.010
Successful laser therapy of a papular acantholytic dyskeratosis of the vulva: case report and review of literature
2009 · Archives of Gynecology and Obstetrics · 32 citations
https://doi.org/10.1007/s00404-009-1313-8
An international comparative analysis and roadmap to sustainable biosimilar markets
2023 · Frontiers in Pharmacology · 22 citations
https://doi.org/10.3389/fphar.2023.1188368
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer
2022 · JAMA Oncology · 20 citations
https://doi.org/10.1001/jamaoncol.2022.1059
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat